Financial Sense Advisors Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,778 shares of the company’s stock after selling 433 shares during the period. Financial Sense Advisors Inc.’s holdings in Johnson & Johnson were worth $2,021,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Kennedy Capital Management LLC increased its stake in shares of Johnson & Johnson by 18.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock worth $3,189,000 after purchasing an additional 3,206 shares during the last quarter. Horizon Family Wealth Inc. bought a new stake in shares of Johnson & Johnson in the third quarter valued at $572,000. Obsidian Personal Planning Solutions LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $521,000. Blueprint Investment Partners LLC grew its stake in shares of Johnson & Johnson by 371.6% during the 3rd quarter. Blueprint Investment Partners LLC now owns 6,277 shares of the company’s stock worth $978,000 after acquiring an additional 4,946 shares during the period. Finally, Westside Investment Management Inc. increased its holdings in Johnson & Johnson by 5.9% in the 3rd quarter. Westside Investment Management Inc. now owns 4,725 shares of the company’s stock worth $736,000 after acquiring an additional 262 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, July 1st. Bank of America dropped their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group assumed coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price for the company. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $174.07.
Read Our Latest Stock Analysis on JNJ
Johnson & Johnson Stock Performance
NYSE JNJ opened at $146.48 on Friday. The company has a market capitalization of $352.53 billion, a P/E ratio of 9.13, a P/E/G ratio of 2.42 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The company has a fifty day moving average of $147.94 and a 200-day moving average of $153.73.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the business earned $2.68 earnings per share. As a group, equities research analysts predict that Johnson & Johnson will post 10.62 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.39%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.
Johnson & Johnson Company Profile
(Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
